Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer/Onyx’ Nexavar Approved For Kidney Cancer

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA’s full approval of the oncologic indicates sorafenib for broad use by all patients with advanced renal cell carcinoma.
Advertisement

Related Content

Bayer/Onyx Submit Nexavar sNDA For Liver Cancer
Onyx/Bayer Expect 2008 Launch For Nexavar In Liver Cancer
Bayer/Onyx Nexavar Fails Phase III Melanoma Trial
Bayer/Onyx Nexavar Hits Sales Plateau After Rapid Initial Uptake
Pfizer’s Sutent Outperforms Conventional Therapy For First-Line Renal Cell Carcinoma
Pfizer Sutent Review: Partial Response Could Mean Clinical Benefit In RCC Setting
Nexavar “Very Competitive” With Pfizer’s Sutent, Bayer Says
Next For Nexavar: Bayer/Onyx Initiate Phase III Lung Cancer Trial
Pfizer's Sutent Receives Dual Approvals For Kidney Cancer & Stomach Cancer
Pfizer Expects Favorable Labeling For Oncologic Sutent

Topics

Advertisement
UsernamePublicRestriction

Register

PS061424

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel